tradingkey.logo

Inmode Ltd

INMD
14.450USD
+0.010+0.07%
Close 11/07, 16:00ETQuotes delayed by 15 min
913.37MMarket Cap
6.11P/E TTM

Inmode Ltd

14.450
+0.010+0.07%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Inmode Ltd

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Inmode Ltd's Score

Industry at a Glance

Industry Ranking
86 / 209
Overall Ranking
183 / 4614
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Hold
Current Rating
16.800
Target Price
+16.26%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Inmode Ltd Highlights

StrengthsRisks
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
Undervalued
The company’s latest PE is 6.01, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 35.31M shares, decreasing 49.11% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.15K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 9.24, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 95.60M, representing a year-over-year increase of 10.59%, while its net profit experienced a year-over-year increase of 12.28%.

Score

Industry at a Glance

Previous score
9.24
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

8.31

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.89

Inmode Ltd's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 6.12, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 6.01, which is 251.95% below the recent high of 21.17 and 5.47% above the recent low of 5.69.

Score

Industry at a Glance

Previous score
6.12
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 86/209
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 6.29, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Inmode Ltd is 16.00, with a high of 21.00 and a low of 15.00.

Score

Industry at a Glance

Previous score
6.29
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts
Hold
Current Rating
16.800
Target Price
+16.26%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

89
Total
4
Median
7
Average
Company name
Ratings
Analysts
Inmode Ltd
INMD
7
Boston Scientific Corp
BSX
37
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
35
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
28
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.12, which is lower than the Healthcare Equipment & Supplies industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 15.77 and the support level at 13.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.12
Change
0

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.241
Sell
RSI(14)
38.536
Neutral
STOCH(KDJ)(9,3,3)
22.386
Neutral
ATR(14)
0.393
High Vlolatility
CCI(14)
-84.070
Neutral
Williams %R
82.949
Oversold
TRIX(12,20)
-0.146
Sell
StochRSI(14)
6.744
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
14.548
Sell
MA10
14.806
Sell
MA20
15.150
Sell
MA50
15.065
Sell
MA100
14.720
Sell
MA200
15.587
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.42. The latest institutional shareholding proportion is 55.87%, representing a quarter-over-quarter decrease of 33.11%. The largest institutional shareholder is James Simons, holding a total of 2.33M shares, representing 3.68% of shares outstanding, with 12.95% increase in holdings.

Score

Industry at a Glance

Previous score
5.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Mizrahy (Moshe)
3.50M
+74.50%
Kreindel (Michael)
3.11M
--
Renaissance Technologies LLC
Star Investors
2.33M
+0.85%
DOMA Perpetual Capital Management, LLC
2.24M
--
BlackRock Institutional Trust Company, N.A.
1.80M
-63.39%
Millennium Management LLC
1.23M
+1325.97%
Systematic Financial Management, L.P.
1.09M
+3.94%
Meitav Investment House Ltd
1.32M
-0.17%
Harel Insurance Investments and Financial Services Ltd
899.99K
--
Hotchkis and Wiley Capital Management, LLC
Star Investors
817.92K
+14.36%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 7.79, which is higher than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 2.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
7.79
Change
0
Beta vs S&P 500 index
2.14
VaR
+5.47%
240-Day Maximum Drawdown
+32.00%
240-Day Volatility
+43.88%

Return

Best Daily Return
60 days
+5.58%
120 days
+5.58%
5 years
+15.51%
Worst Daily Return
60 days
-3.93%
120 days
-4.91%
5 years
-19.97%
Sharpe Ratio
60 days
-0.04
120 days
+0.05
5 years
-0.01

Risk Assessment

Maximum Drawdown
240 days
+32.00%
3 years
+71.16%
5 years
+86.43%
Return-to-Drawdown Ratio
240 days
-0.68
3 years
-0.28
5 years
-0.12
Skewness
240 days
-0.91
3 years
-0.42
5 years
+0.03

Volatility

Realised Volatility
240 days
+43.88%
5 years
+56.64%
Standardised True Range
240 days
+3.83%
5 years
+11.32%
Downside Risk-Adjusted Return
120 days
+9.42%
240 days
+9.42%
Maximum Daily Upside Volatility
60 days
+28.92%
Maximum Daily Downside Volatility
60 days
+21.94%

Liquidity

Average Turnover Rate
60 days
+1.99%
120 days
+2.06%
5 years
--
Turnover Deviation
20 days
-7.90%
60 days
+9.15%
120 days
+12.76%

Peer Comparison

Healthcare Equipment & Supplies
Inmode Ltd
Inmode Ltd
INMD
6.99 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI